Precise Bio

Company Overview

Snapshot

Founded in July 2015 by Aryeh Batt, Anthony Atala, and Shay Soker, Precise Bio operates with 11–50 employees. The company has raised $22 million across four funding rounds from four investors. In July 2022, Precise Bio announced a partnership with Carl Zeiss Meditec for the development and commercialization of tissue-based implants for ophthalmology.

Business overview

Precise Bio is a regenerative medicine company focused on advancing bio-printed tissues and organs for ophthalmology patients, while also developing a broad portfolio of R&D programs in other medical disciplines. The company's core technology is its 4D bio-fabrication platform, which integrates cell expansion, biomaterials, processes, and printing technology. This platform enables the development of fabricated human corneas and other organs and tissues for ophthalmic indications, addressing challenges in scalable and reproducible manufacturing. Precise Bio operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.

Strategic signal

In July 2022, Precise Bio formed a strategic partnership with Carl Zeiss Meditec for the development and commercialization of tissue-based implants for ophthalmology. This collaboration signifies a strong validation of Precise Bio's 4D bio-fabrication technology and its potential to bring advanced regenerative medicine solutions to market, indicating a clear path towards commercialization and broader industry adoption.

Company Intelligence Q&A

What is Precise Bio's core focus?

Precise Bio is a regenerative medicine company that develops bio-fabricated tissues and organs, primarily for ophthalmology patients, and is expanding its R&D into other medical disciplines.

When was Precise Bio founded and by whom?

Precise Bio was founded in July 2015 by Aryeh Batt, Anthony Atala, and Shay Soker.

What significant partnership did Precise Bio announce in July 2022?

In July 2022, Precise Bio announced a partnership with Carl Zeiss Meditec for the development and commercialization of tissue-based implants for ophthalmology.

What is Precise Bio's primary technology platform?

Precise Bio's technology platform is based on its 4D bio-fabrication technology, which includes cell expansion, biomaterials, processes, and printing technology for creating bio-printed tissues and organs.